Claims
- 1. A 2-R-6-PY-3(2H)-pyridazinone having the formula ##STR3## or pharmaceutically-acceptable acid-addition salt thereof, where PY is 4-pyridinyl or 4-pyridinyl having one or two lower-alkyl substituents, and R is hydrogen, lower-alkyl or lower-hydroxyalkyl.
- 2. A compound according to claim 1 where PY is 4-pyridinyl.
- 3. A compound according to claim 1 where R is hydrogen.
- 4. A compound according to claim 1 where R is methyl.
- 5. A compound according to claim 1 where R is ethyl.
- 6. A compound according to claim 1 where R is 2-hydroxyethyl.
- 7. 6-(4-Pyridinyl)-3(2H)-pyridazinone or pharmaceutically-acceptable acid-addition salt thereof.
- 8. 2-Methyl-6-(4-pyridinyl)-3(2H)-pyridazinone or pharmaceutically-acceptable acid-addition salt thereof.
- 9. A cardiotonic composition for increasing cardiac contractility, said composition comprising a pharmaceutically-acceptable inert carrier and, as the active component thereof, an effective amount of a cardiotonic 2-R-6-PY-3-(2H)-pyridazinone or pharmaceutically-acceptable acid-addition salt thereof where R is hydrogen, lower-alkyl or lower-hydroxyalkyl, and PY is 4-pyridinyl or 4-pyridinyl having one or two lower-alkyl substituents.
- 10. The composition according to claim 9 where PY is 4-pyridinyl and R is hydrogen, methyl, ethyl or 2-hydroxyethyl.
- 11. The composition according to claim 9 where the cardiotonic is 6-(4-pyridinyl)-3(2H)-pyridazinone or pharmaceutically-acceptable acid-addition salt thereof.
- 12. The composition according to claim 9 wherein the cardiotonic is 2-methyl-6-(4-pyridinyl)-3(2H)-pyridazinone or pharmaceutically-acceptable acid-addition salt thereof.
- 13. The method for increasing cardiac contractility in a patient requiring such treatment which comprises administering orally or parenterally in a solid or liquid dosage form to such patient an effective amount of a cardiotonic 2-R-6-PY-3(2H)-pyridazinone or pharmaceutically-acceptable acid-addition salt thereof, where R is hydrogen, lower-alkyl or lower-hydroxyalkyl, and PY is 4-pyridinyl or 4-pyridinyl having one or two lower-alkyl substituents.
- 14. The method according to claim 13 where PY is 4-pyridinyl and R is hydrogen, methyl, ethyl or 2-hydroxyethyl.
- 15. The method according to claim 13 where the cardiotonic is 6-(4-pyridinyl)-3(2H)pyridazinone or pharmaceutically-acceptable acid-addition salt thereof.
- 16. The method according to claim 13 where the cardiotonic is 2-methyl-6-(4-pyridinyl)-3(2H)-pyridazinone or pharmaceutically-acceptable acid-addition salt thereof.
CROSS-REFERENCE TO RELATED APPLICATION
This application is a continuation-in-part of copending application Ser. No. 71,065, filed Aug. 30, 1979 and now abandoned.
US Referenced Citations (9)
Foreign Referenced Citations (1)
Number |
Date |
Country |
54-19987 |
Feb 1979 |
JPX |
Non-Patent Literature Citations (3)
Entry |
Curran et al. II, J. Med. Chem. 17, 273 (1974). |
Haginiwa et al., Chem. Abs. 88, 170096 (1978). |
Steck et al., J. Amer. Chem. Soc., 75, 1117 (1953). |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
71065 |
Aug 1979 |
|